The only contraindication is hypersensitivity to<unk>  or any of its excipients. Cautions include: * Hypertension, including hypertensive crises have been reported. * QT interval prolongation and torsades de pointes have been reported. * Thrombotic microangiopathy has been reported. * Thrombotic thrombocytopenic purpura has been reported. * Haemolytic uremic syndrome has been reported. * Haematologic parameter alterations have been reported in 31–37% of patients. * Events of cardiac dysfunction (decreased left ventricular ejection fraction and congestive heart failure) have been observed. * Fatal haemorrhage, arterial and venous thrombotic events and perforations in the gastrointestinal tract have been observed in randomized clinical trials. It has one black box warning by the US FDA, namely severe hepatotoxicity including fatalities.
Pazopanib
Vatalanib
Pegaptanib
Tivozanib
Nintedanib
Abrocitinib
Gilteritinib
Erdafitinib